公开(公告)号：US20230002741A1

公开(公告)日：2023-01-05

申请号：US17827320

申请日：2022-05-27

Applicant: TONIX PHARMACEUTICALS HOLDING CORP. ,  TONIX PHARMA LIMITED

Inventor： David Evans ,  Ryan Noyce ,  Seth Lederman

IPC: C12N7/00 ,  A61K39/275 ,  A61K39/12 ,  A61P31/20

Abstract: The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.

公开(公告)号：US20210260182A1

公开(公告)日：2021-08-26

申请号：US17187678

申请日：2021-02-26

Applicant: Scott J. Goebel ,  David Evans ,  Ryan Noyce ,  Tonix Pharmaceuticals Holding Corp. ,  The Governors of the University of Alberta

Inventor： Seth Lederman ,  Scott J. Goebel ,  David Evans ,  Ryan Noyce

IPC: A61K39/215 ,  C12N7/00 ,  C12N15/85

Abstract: The invention relates in various aspects to a recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, methods for producing such viruses and the use of such viruses. The recombinant poxviruses are well suited, among others, as protective virus vaccines against SARS-CoV-2 virus.